BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 37515110)

  • 1. The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature.
    Martora F; Battista T; Ruggiero A; Scalvenzi M; Villani A; Megna M; Potestio L
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515110
    [No Abstract]   [Full Text] [Related]  

  • 2. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.
    Seirafianpour F; Pourriyahi H; Gholizadeh Mesgarha M; Pour Mohammad A; Shaka Z; Goodarzi A
    Dermatol Ther; 2022 Jun; 35(6):e15461. PubMed ID: 35316551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study.
    McMahon DE; Kovarik CL; Damsky W; Rosenbach M; Lipoff JB; Tyagi A; Chamberlin G; Fathy R; Nazarian RM; Desai SR; Lim HW; Thiers BH; Hruza GJ; French LE; Blumenthal K; Fox LP; Freeman EE
    J Am Acad Dermatol; 2022 Jan; 86(1):113-121. PubMed ID: 34517079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.
    Botton J; Jabagi MJ; Bertrand M; Baricault B; Drouin J; Le Vu S; Weill A; Farrington P; Zureik M; Dray-Spira R
    Ann Intern Med; 2022 Sep; 175(9):1250-1257. PubMed ID: 35994748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
    Nguyen S; Bastien E; Chretien B; Sassier M; Defer G; Nehme A; Lelong-Boulouard V; Alexandre J; Fedrizzi S; Morice PM
    Ann Neurol; 2022 Dec; 92(6):1080-1089. PubMed ID: 36054163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study.
    Lee DS; Kim JW; Lee KL; Jung YJ; Kang HW
    Int J Infect Dis; 2022 May; 118():173-182. PubMed ID: 35276381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
    Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.
    Krzywicka K; Heldner MR; Sánchez van Kammen M; van Haaps T; Hiltunen S; Silvis SM; Levi M; Kremer Hovinga JA; Jood K; Lindgren E; Tatlisumak T; Putaala J; Aguiar de Sousa D; Middeldorp S; Arnold M; Coutinho JM; Ferro JM
    Eur J Neurol; 2021 Nov; 28(11):3656-3662. PubMed ID: 34293217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data.
    Cari L; Alhosseini MN; Fiore P; Pierno S; Pacor S; Bergamo A; Sava G; Nocentini G
    J Autoimmun; 2021 Dec; 125():102742. PubMed ID: 34710832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases.
    Petruzzi M; Galleggiante S; Messina S; Della Vella F
    BMC Oral Health; 2022 Mar; 22(1):90. PubMed ID: 35331228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions.
    Francis AI; Ghany S; Gilkes T; Umakanthan S
    Postgrad Med J; 2022 May; 98(1159):389-394. PubMed ID: 37066438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
    Català A; Muñoz-Santos C; Galván-Casas C; Roncero Riesco M; Revilla Nebreda D; Solá-Truyols A; Giavedoni P; Llamas-Velasco M; González-Cruz C; Cubiró X; Ruíz-Villaverde R; Gómez-Armayones S; Gil Mateo MP; Pesqué D; Marcantonio O; Fernández-Nieto D; Romaní J; Iglesias Pena N; Carnero Gonzalez L; Tercedor-Sanchez J; Carretero G; Masat-Ticó T; Rodríguez-Jiménez P; Gimenez-Arnau AM; Utrera-Busquets M; Vargas Laguna E; Angulo Menéndez AG; San Juan Lasser E; Iglesias-Sancho M; Alonso Naranjo L; Hiltun I; Cutillas Marco E; Polimon Olabarrieta I; Marinero Escobedo S; García-Navarro X; Calderón Gutiérrez MJ; Baeza-Hernández G; Bou Camps L; Toledo-Pastrana T; Guilabert A
    Br J Dermatol; 2022 Jan; 186(1):142-152. PubMed ID: 34254291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.
    Li X; Burn E; Duarte-Salles T; Yin C; Reich C; Delmestri A; Verhamme K; Rijnbeek P; Suchard MA; Li K; Mosseveld M; John LH; Mayer MA; Ramirez-Anguita JM; Cohet C; Strauss V; Prieto-Alhambra D
    BMJ; 2022 Oct; 379():e071594. PubMed ID: 36288813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et al.
    Martora F; Villani A; Marasca C; Fabbrocini G; Ruggiero A
    Australas J Dermatol; 2023 Feb; 64(1):e103-e105. PubMed ID: 36683345
    [No Abstract]   [Full Text] [Related]  

  • 18. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
    Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Immunol; 2022; 13():956825. PubMed ID: 36177033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom.
    Otero-Losada M; Petrovsky N; Alami A; Crispo JA; Mattison D; Capani F; Goetz C; Krewski D; Perez-Lloret S
    Expert Opin Drug Saf; 2023 Apr; 22(4):343-349. PubMed ID: 36043937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
    Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
    EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.